An investigation into the potential of SarAr for use in Cu-64 radioimmunotherapy.
No Thumbnail Available
Date
2009-10-13
Journal Title
Journal ISSN
Volume Title
Publisher
CSIRO Publishing
Abstract
The B72.3 monoclonal antibody was radiolabelled with 123I, and with 111In and 64Cu, using DTPA and SarAr, respectively. Their biodistribution in tumour-bearing nude mice was used to calculate the dosimetry of their respective therapeutic analogue, using 131I, 90Y, 67Cu, and 64Cu. Two dosimetry models were used: one using the classical approach and a second model that takes into consideration the chemical stability of the radiolabelling methods employed and the biological clearance of each radioimmunoconjugate. Results clearly show that the 64Cu-SarAr-B72.3 could be used as a therapeutic agent and, theoretically, be at least as effective as any of the other therapeutic radionuclides currently studied, such as 131I, 90Y, and 67Cu. © 2009, CSIRO Publishing
Description
Keywords
Radioimmunotherapy, Iodine 123, Copper 64, Mice, Dosimetry, Drugs
Citation
Di Bartolo, N., Smith, S. V., Hetherington, E., & Sargeson, A. (2009). An investigation into the potential of SarAr for use in Cu-64 radioimmunotherapy. Australian Journal of Chemistry, 62(10), 1261-1270. doi:10.1071/CH09369